BETA
Australian medical device developer building a microneedle-based wearable platform for continuous molecular monitoring, initially targeting vancomycin drug levels.
Nutromics is a Melbourne-based medical device company developing Lab-on-a-Patch, a wearable platform for continuous molecular monitoring. Founded in 2017 by Peter Vranes and Hitesh Mehta, the company has operations in Melbourne and San Diego. Vranes serves as CEO and Mehta as Chief Operating Officer.
The platform combines minimally invasive microneedles with electrochemical aptamer-based sensors, which use synthetic DNA to recognize specific molecules in interstitial fluid beneath the skin. Its initial clinical product targets therapeutic drug monitoring of vancomycin, an antibiotic whose dosing requires careful control of drug exposure.
Nutromics is also researching creatinine monitoring and multi-analyte sensing for future renal, infectious-disease and cardiovascular applications. The initial vancomycin patch remains investigational despite receiving FDA Breakthrough Device Designation; the company’s newer development timeline targets a potential U.S. launch in early 2028, subject to authorization.
Nutromics announced FDA Breakthrough Device Designation for its vancomycin therapeutic drug monitoring patch in September 2026. The patch remains investigational and is not authorized for commercial distribution. The company’s October 2026 update targets a potential U.S. launch in early 2028, subject to regulatory authorization. [3][4]
A February 2026 Nature Biotechnology paper described a pilot study in six healthy participants. The patches measured vancomycin concentrations in dermal interstitial fluid at five-minute intervals; sensor degradation led the researchers to emphasize the first 12 hours of data. This was an early safety and measurement-feasibility study, rather than evidence of improved dosing outcomes in critically ill patients. [6][1]
Nutromics has also reported human creatinine measurements and is developing a future patch that combines creatinine and vancomycin sensing. These biomarker and multi-analyte programmes remain separate development steps from the initial vancomycin product. [4][10]
Latest recorded source review: 2026-11-04.
Scope: selected product families.
No commercially marketed product portfolio has been established in the reviewed material.
Investigational microneedle patch using DNA-based electrochemical aptamer sensors to measure vancomycin in dermal interstitial fluid. The initial product is intended to support therapeutic drug monitoring; creatinine and multi-analyte versions remain in development. [11][10][6][1][3][4]
Investigational · Vancomycin monitoring in clinical developmentCompany reported human creatinine measurements and plans for combined creatinine and vancomycin sensing. [4]
Company announced FDA designation for its investigational vancomycin monitoring patch. [3]
Nature Biotechnology published an early safety and performance study in six healthy participants. [6]
Company update reported cumulative funding of A$60 million following the acceleration round. [2]
Accessed 11/04/2026
Last substantive review: 11/4/2026